Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Dabigatran etexilate price, strengths & recalls

Generic of Pradaxa

Pharmacies pay $24.01 for 30 capsules of Dabigatran etexilate 150 mg capsule this week, and from $21.46 to $26.88 across its 3 priced strengths and forms. 13 manufacturers make it. 9 recalls are ongoing. Its official label last changed on August 1, 2025.

9 open recallsGeneric
Pharmacies pay$24.01for 30 capsules of 150 mg capsule+0.7% in 4 weeks
Fair cash price
$38.11
Strengths
3
Makers
13
Updated
Nov 11

Dabigatran etexilate price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
75 mg capsule$0.7152$21.46 / 30 capsules-4.7%-36.5%
110 mg capsule$0.8961$26.88 / 30 capsules-4.4%-47.9%
150 mg capsule$0.8005$24.01 / 30 capsules+0.7%-26.6%

The lowest cost per capsule is 75 mg capsule at $0.7152. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Brand names of dabigatran etexilate

A brand and its generic share the active ingredient; the generic is almost always far cheaper.

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
9 ongoing recalls10 recalls on record, latest Aug 5, 2026

Recalls

Showing the 6 most relevant of 10 - all recalls.

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for dabigatran etexilate? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedAugust 1, 2025
Version8 of 8
EffectiveJul 30, 2025
Read the label

These highlights do not include all the information needed to use DABIGATRAN ETEXILATE CAPSULES safely and effectively. See full prescribing information for DABIGATRAN ETEXILATE CAPSULES. DABIGATRAN ETEXILATE capsules, for oral use Initial U.S. Approval: 2010

This drug has a boxed warning

WARNING: (A) PREMATURE DISCONTINUATION OF DABIGATRAN ETEXILATE CAPSULES INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA

(A) PREMATURE DISCONTINUATION OF DABIGATRAN ETEXILATE CAPSULES INCREASES THE RISK OF THROMBOTIC EVENTS

Premature discontinuation of any oral anticoagulant, including dabigatran etexilate capsules, increases the risk of thrombotic events. If anticoagulation with dabigatran etexilate capsules is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant

[see Dosage and Administration (

2.6,

2.7,

2.8) and Warnings and Precautions (

5.1)].

(B) SPINAL/EPIDURAL HEMATOMA

Epidural or spinal hematomas may occur in patients treated with dabigatran etexilate capsules who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

• use of indwelling epidural catheters

• concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants

• a history of traumatic or repeated epidural or spinal punctures

• a history of spinal deformity or spinal surgery

• optimal timing between the administration of dabigatran etexilate capsules and neuraxial procedures is not known

[see Warnings and Precautions (

5.3)].

Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary

[see Warnings and Precautions (

5.3)].

Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated

[see Warnings and Precautions (

5.3)].

WARNING: (A) PREMATURE DISCONTINUATION OF DABIGATRAN ETEXILATE CAPSULES INCREASES THE RISK OF THROMBOTIC EVENTS, and

(B) SPINAL/EPIDURAL HEMATOMA

See full prescribing information for complete boxed warning

(A) PREMATURE DISCONTINUATION OF DABIGATRAN ETEXILATE CAPSULES INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including dabigatran etexilate capsules, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if dabigatran etexilate capsules are discontinued for a reason other than pathological bleeding or completion of a course of therapy (

2.6,

2.7,

2.8,

5.1).

(B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated withdabigatran etexilate capsules who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis (

5.3). Monitor patients frequently for signs and symptoms of neurological impairment and if observed, treat urgently. Consider the benefits and risks before neuraxial intervention in patients who are or who need to be anticoagulated (

5.3).

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA022512 · Boehringer Ingelheim
First approved
October 19, 2010 (16 years ago)
Latest approved change
June 17, 2025
Approved label
PDF, Oct 3, 2025
Generic makers
8 approved generic applications on the market
Last patent listed
July 20, 2031

Dabigatran etexilate questions

How much does dabigatran etexilate cost without insurance?

Pharmacies pay about $24.01 for 30 capsules of dabigatran etexilate 150 mg capsule ($0.8005 per capsule). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $38.11. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

What is the brand name of dabigatran etexilate?

Dabigatran etexilate is sold as Pradaxa. The generic has the same active ingredient and usually costs far less.

Is dabigatran etexilate in shortage?

No shortage is reported for dabigatran etexilate right now. We check the national shortage list every day.

Has dabigatran etexilate been recalled?

10 recalls on record, 9 ongoing. Recalls name specific lots - check yours.

When did the dabigatran etexilate label last change?

The official label was last updated on August 1, 2025 (version 8). See what changed.

Talk about dabigatran etexilate

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.